As discussed earlier, Eli Lilly and Company’s (LLY) 3Q15 segment-by-segment performance was positive for both its human pharmaceuticals and animal health segments.
The graph above outlines some of Eli Lilly’s major developments in 3Q15.
Eli Lilly launched Trulicity in Japan and Humalog U-200 KwikPen in the United States. Eli Lilly also launched Basaglar in the Japan and European markets, and Synjardy in the US market in collaboration with Boehringer Ingelheim. All these drugs are classified in its endocrinology franchise and are used in different treatments of type 1 and type 2 diabetes.
The following are Eli Lilly’s 3Q15 regulatory developments:
- Received FDA (U.S. Food and Drug Administration) approval for Synjardy in collaboration with Boehringer Ingelheim
- Submitted a once-daily, single-pill combination therapy for the treatment of type 2 diabetes, in collaboration with Boehringer Ingelheim, for approval to the FDA
- Submitted ramucirumab for second-line NSCLC (non-small cell lung cancer) treatment, and ixekizumab for psoriatic arthritis and other usages, for approvals in Japan
- Submitted Humulin R U-500 KwikPen for approval to the FDA
- Received breakthough therapy designation from the FDA for Abemaciclib, a drug for treatment of metastatic breast cancer
Other developments for Eli Lilly include the following:
- Clinical developments for baricitinib in collaboration with Incyte Corporation
- Announcement of results of EMPA-REG Outcome study evaluating Jardiance, a cardiovascular drug
- Return of Erbitux’s North American rights to Eli Lilly from Bristol-Myers Squibb (BMY)
- Acquisition of rights for a Phase III intranasal glucagon from Locemia Solutions
- Announcement of other collaborations including Innovent Biologics and ImaginAb
- Immune-oncology expansion in collaboration with AstraZeneca (AZN) to include additional combinations
- Settlement of patent litigation with Sanofi (SNY) regarding the insulin glargine
- Collaboration with Boehringer Ingelheim to launch Basaglar in the US market in December 2016
Apart from these developments, the company also announced plans to expand its research and development site located in New York City to further include immune-oncology discovery and research capabilities.
Investors could consider ETFs such as the VanEck Vectors Pharmaceutical ETF (PPH) which holds 4.9% of its portfolio in Eli Lilly.